Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, nearly 5% of anti-TNF-treated patients with IBD developed psoriasiform skin lesions, with smoking identified as a main risk factor, and ustekinumab proved highly effective in severe cases.

In this study, only 1 out of 5 patients with anti-TNF-α induced psoriasiform eruptions showed good response to topical treatment, while systemic therapy and discontinuation of anti-TNF-α may prevent scarring alopecia in severe cases.

This review discusses the dermatological adverse events from immunosuppressive and anti-TNF therapy in IBD, finding increased risks of non-melanoma skin cancer and other skin conditions, and recommends regular cancer screening.

In this study, weight gain and hair loss were reported as adverse effects of anti-TNF therapy in patients with rheumatic diseases, leading some to discontinue treatment.

In this case report, a patient with Crohn's disease experienced alopecia and psoriasiform reactions attributed to anti-TNF therapy, which improved after switching to Ustekinumab.

This study, involving a retrospective analysis of 24 patients in France, found that paradoxical psoriasiform alopecic reactions on the scalp associated with TNFα-targeted therapies for inflammatory bowel disease are rare yet non-scarring, with all patients achieving complete hair regrowth within two months after treatment adjustments.

This study found that anti-TNF therapy-induced alopecia exhibits distinct clinical and histopathological features and can mimic psoriatic alopecia and alopecia areata, with some patients improving with topical treatment.

This study reports two cases of alopecia associated with anti-TNF therapy, highlighting a new entity combining features of alopecia areata and psoriatic alopecia.

This article examines anticytokine therapies for autoimmune diseases, highlighting the potential of anti-interferon-γ as a universal treatment for certain conditions and noting varying effectiveness of tumor necrosis factor-α inhibitors.

This case series highlights that anti-TNF agents, though beneficial for autoimmune conditions, can cause a rare adverse reaction of psoriasiform alopecia areata, stressing the importance of specific histopathological features for accurate diagnosis and better management to avoid unnecessary drug discontinuation.

This study found that the new cocrystal formulation KET-PABA improved the antimycotic efficiency of ketoconazole and induced an anti-inflammatory response without causing skin sensitization in mice.

This review suggests that immunomodulators, including TNF-α blockers and IL inhibitors, may improve symptoms of moderate-to-severe dissecting cellulitis of the scalp, but their effects on hair regrowth and scarring remain unclear.

This study suggests that ethanol extracts from ten selected Korean herb medicines reduced inflammatory markers in a cell model and did not cause skin irritation in human testing, indicating potential cosmetic use for irritation prevention.

In scalded rats, this study found that early melatonin administration may reduce oxidative stress and inflammation, thus protecting hair follicle cells after severe burns.

This study found that compounds isolated from Osmanthus fragrans var. aurantiacus demonstrated antioxidative and anti-inflammatory activities, potentially offering therapeutic benefits for inflammatory bowel diseases by inhibiting COX-2 and iNOS enzymes and blocking ERK 1/2 MAPK signaling.

This study reported that a newly designed multifunctional conductive hydrogel, PrM, combined with electrical stimulation significantly accelerated wound healing, achieving 95.9% healing in a mouse model on day 10, by enhancing regenerative processes and downregulating TNF-α signaling under electrical treatment.

In this study, ginger peel polysaccharides modified with zinc reduced inflammation in zebrafish by altering cytokine expression, suggesting potential for treating chronic inflammation-related diseases.

In this study, PBMCs from women with PCOS showed reduced TNF-α production over time, potentially limiting their antitumor response to breast cancer cell lines compared to healthy controls.

This study highlights cases of alopecia areata that developed during anti-TNF-α therapy, suggesting a potential link or increased frequency, particularly among individuals with a personal or family history of autoimmune diseases.

This review explores the connection between psoriasis and hair loss, noting that both the disease and its treatments can contribute to alopecia, and reports no new clinical results.

This report describes a case of universal alopecia in a patient with rheumatoid arthritis while using adalimumab and leflunomide, suggesting a potential link between these drugs and alopecia areata.

This case report describes a patient with psoriasis who developed alopecia with unique histological features after anti-TNF therapy, suggesting that such effects may require considering treatment suspension for severe cases.

This case report describes a 37-year-old woman who developed scalp psoriasis and severe alopecia after taking adalimumab, with complete hair regrowth following treatment change.

This study found that hair loss is common among patients with inflammatory bowel disease, with mesalamine and anti-TNF medications associated with lower odds of experiencing hair loss.

This review outlines the various adverse reactions to biologic therapies in Allergy/Immunology, emphasizing the clinical and management challenges due to overlapping reaction phenotypes and the need for more refined diagnostic and management strategies.

This study analyzed adverse event reports from the FDA database and found that drugs such as immunomodulatory agents, monoclonal antibodies, minoxidil, contraceptives, and anti-TNF drugs are frequently associated with hair loss, suggesting guidance for dermatologists in identifying common medications linked to alopecia.

IBD patients treated with TNF antagonists may develop autoimmune alopecia areata, with severe cases less likely to improve.

Some patients on anti-TNF drugs experience a type of hair loss called TAIAPA.

This case report describes a patient with Crohn's disease developing alopecia and psoriasiform skin lesions while on adalimumab treatment.

This article reviews historical uses of the term "lupus" for various skin disorders but provides no new clinical findings.